New Zealand markets open in 6 hours 11 minutes

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
182.79+2.05 (+1.14%)
As of 09:48AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close180.74
Bid182.01 x 900
Ask183.57 x 1200
Day's range181.19 - 184.58
52-week range121.98 - 212.00
Avg. volume604,015
Market cap21.862B
Beta (5Y monthly)0.96
PE ratio (TTM)N/A
EPS (TTM)-7.13
Earnings date09 Feb 2022 - 14 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est207.10
  • Business Wire

    Alnylam to Webcast Presentations at Upcoming Investor Conferences

    CAMBRIDGE, Mass., November 23, 2021--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:

  • Motley Fool

    4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

    The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.

  • Motley Fool

    Why Dicerna Pharmaceuticals Stock Is Rocketing Higher Today

    Shares of Dicerna Pharmaceuticals (NASDAQ: DRNA), a clinical-stage biopharmaceutical company, are exploding higher today in response to a buyout offer from Novo Nordisk (NYSE: NVO). Today, Novo Nordisk agreed to acquire all of Dicerna's outstanding shares for $38.25 each. At the moment, Dicerna's pipeline has a handful of midstage candidates and one in late-stage trials called nedosiran.